Evolution of Biomarkers of Atherogenic Risk in Liver Transplantation Recipients

Carregando...
Imagem de Miniatura
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Citação
TRANSPLANTATION PROCEEDINGS, v.50, n.10, p.3650-3655, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Cardiovascular disease is a major contributing factor to long-term mortality after liver transplantation (LT). Methods. This study evaluated the evolution of atherogenic risk in liver transplant recipients (LTRs). Thirty-six subjects were prospectively enrolled at 12 months and followed for 48 months after liver transplantation. Serum biomarkers of endothelial dysfunction (sICAM-1 and sVCAM-1), chronic inflammation (serum amyloid A), and oxidative stress (myeloperoxidase) were measured at 12 and 48 months after LT. Additionally, at 12 months all patients underwent a cardiac computed tomography (CT) scan and a coronary artery calcium score (CACS). Results. The prevalence of risk factors of metabolic syndrome (MS) increased over the course of the study. The patients' sVCAM-1 and sICAM-1 increased from 1.82 +/- 0.44 ng/mL to 9.10 +/- 5.82 ng/mL (P < .001) and 0.23 +/- 0.09 ng/mL to 2.7 +/- 3.3 ng/mL, respectively from month 12 to 48. Serum myeloperoxidase increased from 0.09 +/- 0.07 ng/mL to 3.46 +/- 3.92 ng/mL (P < .001) over the course of the study. Serum amyloid A also increased from 21.4 +/- 40.7 ng/mL at entry to 91.5 +/- 143.6 ng/mL at end of study (P < .001). Conclusion. No association between these biomarkers and MS was noted. The cardiac CT revealed mild and moderate disease in 19% and 25% of the cohort, respectively. No association between serum biomarkers and CACS was noted. Serum biomarkers of atherogenic risk increase rapidly in LTRs and precede coronary plaques.
Palavras-chave
Referências
  1. Aberg F, 2015, HEPATOLOGY, V61, P668, DOI 10.1002/hep.27538
  2. AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T
  3. Baid S, 2001, TRANSPLANTATION, V72, P1066, DOI 10.1097/00007890-200109270-00015
  4. Bhati C, 2017, TRANSPLANTATION, V101, P1867, DOI 10.1097/TP.0000000000001709
  5. Bianchi G, 2008, LIVER TRANSPLANT, V14, P1648, DOI 10.1002/lt.21588
  6. Chhatrala R, 2015, LIVER TRANSPLANT, V21, P623, DOI 10.1002/lt.24100
  7. Connolly GM, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-23
  8. Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
  9. Dare AJ, 2014, LIVER TRANSPLANT, V20, P281, DOI 10.1002/lt.23818
  10. Detrano RC, 2004, AM J CARDIOL, V93, P624, DOI 10.1016/j.amjcard.2003.11.034
  11. Fussner LA, 2015, LIVER TRANSPLANT, V21, P889, DOI 10.1002/lt.24137
  12. Greenland P, 2004, JAMA-J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210
  13. Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198
  14. Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
  15. Idowu MO, 2015, LIVER TRANSPLANT, V21, P1395, DOI 10.1002/lt.24223
  16. Kosuge M, 2007, CIRC J, V71, P186, DOI 10.1253/circj.71.186
  17. Laryea M, 2007, LIVER TRANSPLANT, V13, P1109, DOI 10.1002/lt.21126
  18. Leber AW, 2005, J AM COLL CARDIOL, V46, P147, DOI 10.1016/j.jacc.2005.03.071
  19. Martin P, 2014, HEPATOLOGY, V59, P1144, DOI 10.1002/hep.26972
  20. Ogawa H, 1999, AM J CARDIOL, V83, P38, DOI 10.1016/S0002-9149(98)00779-6
  21. Siddiqui MS, 2016, GASTROENTEROLOGY, V150, P1849, DOI 10.1053/j.gastro.2016.02.077
  22. Stankovic S, 2012, CLIN LAB, V58, P125
  23. Watt KDS, 2010, AM J TRANSPLANT, V10, P1420, DOI 10.1111/j.1600-6143.2010.03126.x
  24. Watt KDS, 2009, GASTROENTEROLOGY, V137, P2010, DOI 10.1053/j.gastro.2009.08.070
  25. Wawrzynowicz-Syczewska M, 2009, ANN TRANSPL, V14, P45
  26. Zhang YX, 1999, ATHEROSCLEROSIS, V145, P375, DOI 10.1016/S0021-9150(99)00105-7